THM Capital Advisory advises PLASANA MEDICAL to finalize its €4m equity fundraising

Plasana Medical raises €4m in equity, complemented by non-dilutive funding, to advance the development of its cold plasma technology for chronic wound healing.

Plasana Medical, a medtech spin-off from the Plasma Physics Laboratory of École Polytechnique & CNRS, created by the startup-studio TechnoFounders, has completed an equity fundraising of €4m from TF Participations funds (managed by TechnoFounders), alongside family offices and business angels. Plasana also raised non-dilutive funding (grants and bank loans).

The company is developing Plasana One®, an innovative medical device designed to treat chronic wounds (diabetic foot ulcers, venous leg ulcers, pressure ulcers). Leveraging its proprietary multi-jet cold plasma technology, the device accelerates healing by 30-50% while reducing infection risks. Unlike existing solutions, Plasana One® is fast (6-12x quicker), painless, and suitable for home use, where most patients are treated.

Yves Matton (Ecole Polytechnique) co-founded TechnoFounders 10 years ago and launched several deeptech ventures, including Plasana Medical: he was appointed CEO of the Company in May this year.

The proceeds of this round will fund the ongoing PLASANA GENESIS clinical trial aimed at obtaining CE marking in 2026, the preparation for commercialization in Europe and the regulatory process in the United States.

COMPANY ADVISORS: Financial: THM Capital Advisory (Thomas Mitard, Aurélien Prost, Ali Koçak)